A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

• Status: Terminated
• Trial end date: 2018-11-08
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will track bariatric patients who received sugammadex versus neostigmine in the post anesthesia care unit until discharge and assess their length of stay and possible nausea / vomiting / hypoxia episodes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Adam Thaler; Virtua Health, Inc.
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Neostigmine

Criteria

Inclusion Criteria:

• Patients having sleeve gastrectomy

• Surgeries performed by a particular surgeon - Dr. Sam Wasser

• Body Mass Index greater than 35

• American Society of Anesthesiologists Score II and III patients

Exclusion Criteria:

• Patients having a different type of bariatric surgery including but not limited to duodenal switch, gastric bypass, hand-assisted laparoscopic sleeve gastrectomy

• Sleeve gastrectomy's performed by other surgeons than Dr. Sam Wasser.

• Pregnancy

• Allergic to sugammadex, Zofran or scopolamine

• Chronic Obstructive Pulmonary Disease or Asthma that is uncontrolled

• American Society of Anesthesiologists Score I, IV, V patients